SCHEDULE: Vanguard Discloses 5.35% Stake in Alnylam Pharmaceuticals

Vanguard Capital Management has reported beneficial ownership of 5.35% of Alnylam Pharmaceuticals' common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 7,104,536 shares of Alnylam Pharmaceuticals Inc. common stock.
• This holding represents 5.35% of the total class of securities.
• The filing indicates sole voting power over 1,157,830 shares and sole dispositive power over 7,104,536 shares.
• The reporting date for this ownership stake is March 31, 2026.
• Vanguard Capital Management is classified as an investment adviser and an investment company.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, indicating confidence from a major institutional investor in Alnylam Pharmaceuticals' long-term prospects.

Positives

• Significant institutional ownership by a major asset manager like Vanguard can provide stability and confidence to the market.
• Vanguard's investment suggests a positive long-term outlook on Alnylam Pharmaceuticals' business prospects.

Negatives

• The filing does not contain any negative financial or operational information about Alnylam Pharmaceuticals itself, as it is a disclosure of ownership by Vanguard.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks related to Alnylam Pharmaceuticals' operations or the market.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Alnylam Pharmaceuticals.

Industry Context

StockSavvy.ai notes that significant institutional investment, such as Vanguard's increased stake, is common in the biotechnology sector as large asset managers identify promising companies with strong growth potential. Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, a field experiencing substantial innovation and investment.

Stakeholder Impact

• Shareholders may view Vanguard's increased stake as a positive endorsement, potentially increasing investor confidence.
• The investment by a large institution could influence future analyst coverage and market perception of Alnylam Pharmaceuticals.

Next Steps

• Continued monitoring of Vanguard's ownership levels in Alnylam Pharmaceuticals.
• Tracking Alnylam Pharmaceuticals' ongoing research, development, and commercialization activities.

Key Dates

Recommendation

This filing indicates a significant institutional investment by Vanguard, suggesting confidence in Alnylam Pharmaceuticals. However, as a Schedule 13G, it does not provide operational or financial performance details of Alnylam itself. Therefore, while positive, it warrants a 'hold' recommendation pending further analysis of the company's fundamentals and strategic execution.

Keywords

Alnylam Pharmaceuticals, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology